US Patent

US10683302 — Inhibitors of the menin-MLL interaction

Composition of Matter · Assigned to Vitae Pharmaceuticals LLC · Expires 2037-06-08 · 11y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects inhibitors of the menin-MLL interaction, pharmaceutical compositions containing them, and their use in treating cancer and other diseases.

USPTO Abstract

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Drugs covered by this patent

Patent Metadata

Patent number
US10683302
Jurisdiction
US
Classification
Composition of Matter
Expires
2037-06-08
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Vitae Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.